Megan A. Cooper, M.D., Ph.D.  cooper_m@wustl.edu

Profile picture
Associate Professor, Rheumatology
Rheumatology

phone: (314) 454-6124

Clinical Interests

Dr. Cooper received her MD and PhD training at The Ohio State University in Columbus, Ohio. Her PhD work focused on understanding the biology of a subset of human immune cells known as “natural killer” or NK cells. After graduating from medical school she moved to St. Louis and completed her residency and fellowship training at St. Louis Children’s Hospital and Washington University. Dr. Cooper has a clinical interest in primary disorders of the immune system and sees patients in the rheumatology and immunology clinics. She is the Director of the Clinical Immunology program and the Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies at St. Louis Children's Hospital.

Education

  • BA, The College of Wooster1995
  • PhD, The Ohio State University2002
  • MD, Cum Laude, AOA, MD/PhD Fellow, The Ohio State University2004

Training

  • Resident in Pediatrics, St. Louis Children's Hospital, Washington University2004 - 2006
  • Fellowship in Pediatric Rheumatology, Washington University2006 - 2010

Licensure and Board Certification

  • American Board of Pediatrics, General Pediatrics 2007
  • MO, Missouri State Medical License 2010
  • American Board of Pediatrics - Pediatric Rheumatology 2011

Honors

  • National Merit Finalist1991
  • Lewis LaShell Chemistry Scholarship, The College of Wooster1994
  • National Science Foundation Research Undergraduate Fellowship1994
  • Phi Beta Kappa National Honor Society1995
  • Bertha Bouroncle Internal Medicine Research Fellowship1998 - 1999
  • 1st Place, Oral Presentation, Landare Day Medical Student Research Forum1999
  • Howard Hughes Medical Institute (HHMI) Medical Student Research Fellow1999 - 2000
  • American Society of Hematology (ASH) Medical Student Award2001
  • Carroll L. Birch Award, for the best original research paper by a student member of the American Medical Women's Association (AMWA)2001
  • Roche Molecular Biochemicals Distinguished Graduate Seminar Award2001
  • Phi Kappa Phi National Graduate Honor Society2002
  • Alpha Omega Alpha (AOA) Honor Medical Society2003
  • Grant Morrow III, MD, Award for Excellence in Pediatrics, The Ohio State University2004
  • Internal Medicine Research Award, The Ohio State University2004
  • Medical Scientist Award, The Ohio State University College of Medicine2004
  • Watman Achievement Award, Alpha Omega Alpha Society, The Ohio State University2004
  • David Gilstrap Award, Washington University School of Medicine Department of Pediatrics2007
  • Pediatric NIH Loan Repayment Grant (LRP), NIH/NIAID2007 - 2013
  • Scholar of the NIH Child Health Research Center, Washington University Department of Pediatrics2009 - 2013
  • Best Original Basic Science Abstract, Washington University Department of Pediatrics Research Retreat2010
  • Children's Discovery Institute and St. Louis Children's Hospital Faculty Recruit Award2010 - 2015
  • Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital Interdisciplinary Research Award2012 - 2015
  • The American Association of Immunologists (AAI) Early Career Faculty Travel Grant2014
  • “Lecturer of the Month”, St. Louis Children’s Hospital Residency Program, March 20162016
  • Moderator, "Advances in clinical care through whole exome sequencing", American College of Rheumatology (ACR) Annual Meeting, November 15, 2016.2016
  • Moderator, "Immunogenetic Basic Science Symposium", American Society for Histocompatibility & Immunogenetics (ASHI), September 26, 2016.2016
  • Moderator, Guided Poster Tour, 2017 Clinical Immunology Society Meeting, March 25, 2017.2017

Recent Publications view all (34)


  1. Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. JCI Insight. 2018;3(15). PMID:30089725 
  2. Jakinibs for the Treatment of Immunodysregulation in Patients with Gain of Function STAT1 or STAT3 Mutations. J Allergy Clin Immunol. 2018. PMID:30092289 
  3. Comment on: Evidence of innate lymphoid cell redundancy in humans. Nat Immunol. 2018;19(8):788-789. PMID:30026477 
  4. Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. JCI Insight. 2017;2(23). PMID:29212951 
  5. Somatic mutations and clonal hematopoiesis in congenital neutropenia. Blood. 2017. PMID:29092827 
  6. Low IgE Is Insufficiently Sensitive to Guide Genetic Testing of STAT3 Gain-of-Function Mutations. Clin Chem. 2017;63(9):1539-1540. PMID:28667185 
  7. Azathioprine-Associated Complete NK Cell Deficiency. J Clin Immunol. 2017;37(6):514-516. PMID:28639167 
  8. Germline hypomorphic CARD11 mutations in severe atopic disease. Nat Genet. 2017. PMID:28628108 
  9. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest. 2017;127(3):912-928. PMCID:PMC5330730  PMID:28165339 
  10. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123. PMCID:PMC5436500  PMID:27655849 
  11. Mesenteric vasculitis in children with systemic lupus erythematosus. Clin Rheumatol. 2016;35(3):785-93. doi:10.1007/s10067-015-2892-3  PMID:25687984 
  12. Activation-specific metabolic requirements for NK Cell IFN-γ production. J Immunol. 2015;194(4):1954-1962. doi:10.4049/jimmunol.1402099  PMID:25595780 
  13. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125(4):591-599. doi:10.1182/blood-2014-09-602763  PMID:25359994 
  14. Elevated double negative T cells in pediatric autoimmunity. J Clin Immunol. 2014;34(5):594-9. doi:10.1007/s10875-014-0038-z  PMCID:PMC4047151  PMID:24760111 
  15. L-plastin is essential for alveolar macrophage production and control of pulmonary pneumococcal infection. Infect Immun. 2014;82(5):1982-93. PMCID:PMC3993441  PMID:24595139 
  16. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20(4):463-73. doi:10.1016/j.bbmt.2014.01.006  PMCID:PMC3959288  PMID:24434782 
  17. Hypogammaglobulinemia in pediatric systemic lupus erythematosus. Lupus. 2013;22(13):1382-7. doi:10.1177/0961203313507990  PMCID:PMC3840537  PMID:24106215 
  18. Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation. J Immunol. 2013;190(9):4754-62. doi:10.4049/jimmunol.1201742  PMCID:PMC3633638  PMID:23530145 
  19. Cytokine activation induces human memory-like NK cells. Blood. 2012;120(24):4751-60. doi:10.1182/blood-2012-04-419283  PMCID:PMC3520618  PMID:22983442 
  20. Vancomycin-induced DRESS with evidence of T-cell activation in a 22-month-old patient. Ann Allergy Asthma Immunol. 2012;109(4):280-1. doi:10.1016/j.anai.2012.07.016  PMID:23010236 
  21. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009;106(6):1915-9. doi:10.1073/pnas.0813192106  PMCID:PMC2644138  PMID:19181844 
  22. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107-11. doi:10.1002/art.22856  PMID:17763414 
  23. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8):3052-7. doi:10.1182/blood-2002-09-2876  PMID:12480696 
  24. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100(10):3633-8. doi:10.1182/blood-2001-12-0293  PMID:12393617 
  25. Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system. Cytometry. 2001;45(4):285-93. PMID:11746098 
  26. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633-40. PMID:11698225 
  27. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146-51. PMID:11342442 
  28. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. Eur J Immunol. 2001;31(3):792-801. PMID:11241284 
  29. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med. 2001;193(2):219-31. PMCID:PMC2193336  PMID:11208862 
  30. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood. 2000;96(4):1465-73. PMID:10942393 
  31. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest. 2000;106(1):117-24. doi:10.1172/JCI6218  PMCID:PMC314354  PMID:10880055 
  32. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J Immunol. 2000;164(4):1643-7. PMID:10657604 
  33. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162(8):4511-20. PMID:10201989 
  34. Intramolecular energy transfer to trans-stilbene J Phys Chem A. 1998;102:5577-5584. 
Last updated: 08/13/2018
© 2018 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130